Key facts
- Pluslife’s last known valuation is $172.3M (Oct 2022).
- It has raised $40.2M; the latest was Later Stage VC ($14.0M) in Nov 2025.
- Notable investors include Qiming Venture Partners, Puhua Capital, Star River Group, FC Innovation Venture Fund, Guangzhou Hi-tech Investment Group.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pluslife
- ·The full record, as it builds
Funding rounds
No funding rounds for Pluslife are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pluslife
Developer of a molecular diagnostics ecosystem intended for patient testing for human and veterinary health. The company offers portable assay devices, nucleic acid testing workflows, consumable test cards, integrated operating software, and data management capabilities that support use in clinics, community sites, and laboratories, enabling healthcare providers and public health programs to operate in resource-constrained settings and improve continuity of care across diverse environments.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2017
- Employees
- 12
- Website
- pluslife.com/
- Ownership
- Privately Held (backing)
Pluslife doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pluslife shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pluslife in its N-PORT filings yet. We sweep new filings monthly.